ADM
MCID: DRM010
MIFTS: 61

Dermatomyositis (ADM)

Categories: Bone diseases, Eye diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Dermatomyositis

MalaCards integrated aliases for Dermatomyositis:

Name: Dermatomyositis 12 74 52 53 58 54 43 15 17 71
Amyopathic Dermatomyositis 12 52 71
Adult Dermatomyositis 52 58
Dermatopolymyositis 12 32
Polymyositis with Skin Involvement 12
Dermatomyositis Sine Myositis 52
Adult Type Dermatomyositis 71
Adm 52

Characteristics:

Orphanet epidemiological data:

58
dermatomyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (Australia),1-9/100000 (Australia),1-9/1000000 (Argentina),1-5/10000 (Argentina),1-9/1000000 (United States),1-9/1000000 (Spain); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare renal diseases
Rare systemic and rhumatological diseases
Rare skin diseases


Summaries for Dermatomyositis

NINDS : 53 Dermatomyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness.  Dermatomyositis’ cardinal symptom is a skin rash that precedes, accompanies, or follows  progressive muscle weakness.  The rash looks patchy, with purple or red discolorations, and characteristically develops on the eyelids and on muscles used to extend or straighten joints, including knuckles, elbows, knees, and toes.  Red rashes may also occur on the face, neck, shoulders, upper chest, back, and other locations, and there may be swelling in the affected areas.  The rash sometimes occurs without obvious muscle involvement.  Adults with dermatomyositis may experience weight loss, a low-grade fever, inflamed lungs, and be sensitive to light such that the rash or muscle disease gets worse.  Children and adults with dermatomyositis may develop calcium deposits, which appear as hard bumps under the skin or in the muscle (called calcinosis).  Calcinosis most often occurs 1-3 years after the disease begins.  These deposits are seen more often in children with dermatomyositis than in adults.  In some cases of dermatomyositis, distal muscles (muscles located away from the trunk of the body, such as those in the forearms and around the ankles and wrists) may be affected as the disease progresses.  Dermatomyositis may be associated with collagen-vascular or autoimmune diseases, such as lupus.

MalaCards based summary : Dermatomyositis, also known as amyopathic dermatomyositis, is related to hypertension, essential and endocrine organ benign neoplasm, and has symptoms including pruritus and exanthema. An important gene associated with Dermatomyositis is RN7SL1 (RNA Component Of Signal Recognition Particle 7SL1), and among its related pathways/superpathways are MicroRNAs in cancer and miRNAs involved in DNA damage response. The drugs Prednisone and Abatacept have been mentioned in the context of this disorder. Affiliated tissues include muscle, skin where a skin rash is often seen prior to the onset of muscle weakness and lung, and related phenotypes are emg abnormality and erythema

Disease Ontology : 12 A myositis that results in inflammation located in muscle or located in skin where a skin rash is often seen prior to the onset of muscle weakness. The disease may result from either a viral infection or an autoimmune reaction.

NIH Rare Diseases : 52 Amyopathic dermatomyositis is a form of dermatomyositis characterized by the presence of typical skin findings without muscle weakness. Some of the skin changes that suggest dermatomyositis include a pink rash on the face, neck, forearms and upper chest; Gottron's papules and heliotrope eyelids . Pruritis and photosensitivity are common, as is scalp inflammation and thinning of the hair. While patients with amyopathic dermatomyositis should not have clinically evident muscle weakness, minor muscle abnormalities may be included. Fatigue is reported in at least 50% of patients. Some cases have been associated with internal malignancy and/or interstitial lung disease. Treatment may include sun avoidance, ample use of sunscreen, topical corticosteroids , antimalarial agents, methotrexate , mycophenolate mofetil , or intravenous (IV) immunoglobulin .

Wikipedia : 74 Dermatomyositis (DM) is a long-term inflammatory disorder which affects muscles. Its symptoms are... more...

Related Diseases for Dermatomyositis

Diseases in the Dermatomyositis family:

Adult Dermatomyositis

Diseases related to Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 992)
# Related Disease Score Top Affiliating Genes
1 hypertension, essential 32.1 MIR30A MIR223 MIR222 MIR221 MIR214 MIR210
2 endocrine organ benign neoplasm 31.9 MIR335 MIR221 MIR210 MIR21
3 polymyositis 31.6 RN7SL1 MIR30A MIR222 MIR221 MIR214 MIR210
4 cardiovascular system disease 31.6 MIR34A MIR30A MIR223 MIR221 MIR210 MIR21
5 inclusion body myositis 30.6 MIR34A MIR223 MIR222 MIR221 MIR214 MIR21
6 rectum cancer 30.4 MIR221 MIR214 MIR21
7 lymphoma, hodgkin, classic 30.3 MIR30A MIR21 MIR155
8 iga glomerulonephritis 30.3 MIR30A MIR214 MIR148B
9 pulmonary fibrosis, idiopathic 30.2 MIR30A MIR214 MIR21 MIR130A
10 bone cancer 30.1 MIR335 MIR210 MIR21 MIR155
11 connective tissue disease 30.1 MIR34A MIR335 MIR30A MIR223 MIR222 MIR221
12 cervix carcinoma 30.0 MIR362 MIR214 MIR155
13 bone resorption disease 30.0 MIR335 MIR222 MIR214
14 lung cancer susceptibility 3 30.0 MIR362 MIR30A MIR21 MIR154 MIR148A MIR146B
15 diffuse large b-cell lymphoma 30.0 MIR222 MIR221 MIR214 MIR210 MIR21 MIR155
16 retinal vascular disease 29.9 MIR30A MIR21 MIR146B
17 glioma 29.8 MIR34A MIR222 MIR221 MIR210 MIR21 MIR146B
18 melanoma 29.7 MIR34A MIR222 MIR221 MIR210 MIR199B MIR154
19 ovarian disease 29.6 MIR30A MIR223 MIR222 MIR21 MIR132
20 lymphoma, non-hodgkin, familial 29.6 MIR34A MIR30A MIR222 MIR214 MIR21 MIR155
21 gastric cancer 29.6 MIR34A MIR30A MIR223 MIR222 MIR221 MIR214
22 non-alcoholic fatty liver disease 29.6 MIR34A MIR30A MIR21 MIR155 MIR154 MIR132
23 cervical cancer 29.5 MIR34A MIR30A MIR214 MIR21 MIR155 MIR146B
24 esophageal cancer 29.5 MIR34A MIR30A MIR223 MIR21 MIR155 MIR148A
25 clear cell renal cell carcinoma 29.5 MIR30A MIR221 MIR210 MIR21 MIR155
26 renal cell carcinoma, nonpapillary 29.4 MIR34A MIR335 MIR30A MIR221 MIR214 MIR210
27 leukemia, chronic lymphocytic 29.2 MIR34A MIR30A MIR223 MIR221 MIR214 MIR21
28 eye disease 29.2 MIR335 MIR30A MIR223 MIR214 MIR210 MIR21
29 pancreatic ductal adenocarcinoma 29.2 MIR223 MIR222 MIR221 MIR210 MIR21 MIR155
30 myocardial infarction 29.1 MIR34A MIR30A MIR223 MIR221 MIR210 MIR21
31 ovarian cancer 29.0 MIR34A MIR335 MIR30A MIR223 MIR222 MIR221
32 squamous cell carcinoma, head and neck 28.9 MIR30A MIR299 MIR221 MIR214 MIR210 MIR21
33 leukemia, acute lymphoblastic 28.9 MIR335 MIR223 MIR222 MIR221 MIR210 MIR21
34 hepatocellular carcinoma 28.8 MIR34A MIR30A MIR223 MIR222 MIR221 MIR214
35 central nervous system disease 28.6 MIR34A MIR335 MIR30A MIR223 MIR221 MIR210
36 prostate cancer 28.6 MIR34A MIR335 MIR30A MIR223 MIR222 MIR221
37 arteries, anomalies of 28.5 MIR34A MIR30A MIR223 MIR222 MIR221 MIR214
38 facioscapulohumeral muscular dystrophy 1 28.5 MIR34A MIR335 MIR222 MIR221 MIR214 MIR21
39 pancreatic cancer 28.5 MIR34A MIR30A MIR223 MIR222 MIR221 MIR214
40 gastrointestinal system disease 28.3 MIR34A MIR335 MIR30A MIR223 MIR222 MIR221
41 nervous system disease 28.3 MIR34A MIR335 MIR30A MIR223 MIR222 MIR221
42 muscular dystrophy, duchenne type 28.2 MIR34A MIR335 MIR30A MIR299 MIR222 MIR221
43 leukemia, acute myeloid 28.1 MIR34A MIR335 MIR30A MIR223 MIR222 MIR221
44 lung cancer 27.9 MIR362 MIR34A MIR335 MIR30A MIR223 MIR222
45 hematologic cancer 27.8 MIR362 MIR34A MIR335 MIR30A MIR223 MIR222
46 childhood type dermatomyositis 12.9
47 adult dermatomyositis 12.5
48 neonatal dermatomyositis 12.3
49 complement component 9 deficiency 12.1
50 myositis 12.1

Comorbidity relations with Dermatomyositis via Phenotypic Disease Network (PDN):


Acute Cystitis Polymyositis

Graphical network of the top 20 diseases related to Dermatomyositis:



Diseases related to Dermatomyositis

Symptoms & Phenotypes for Dermatomyositis

Human phenotypes related to Dermatomyositis:

58 31 (show top 50) (show all 51)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 emg abnormality 58 31 hallmark (90%) Very frequent (99-80%) HP:0003457
2 erythema 58 31 hallmark (90%) Very frequent (99-80%) HP:0010783
3 autoimmunity 58 31 hallmark (90%) Very frequent (99-80%) HP:0002960
4 myalgia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003326
5 periorbital edema 58 31 hallmark (90%) Very frequent (99-80%) HP:0100539
6 proximal muscle weakness 58 31 hallmark (90%) Very frequent (99-80%) HP:0003701
7 inflammatory myopathy 58 31 hallmark (90%) Very frequent (99-80%) HP:0009071
8 abnormal eyelid morphology 31 hallmark (90%) HP:0000492
9 muscular hypotonia 58 31 frequent (33%) Frequent (79-30%) HP:0001252
10 arthritis 58 31 frequent (33%) Frequent (79-30%) HP:0001369
11 recurrent respiratory infections 58 31 frequent (33%) Frequent (79-30%) HP:0002205
12 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
13 acrocyanosis 58 31 frequent (33%) Frequent (79-30%) HP:0001063
14 abnormality of the nail 58 31 frequent (33%) Frequent (79-30%) HP:0001597
15 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
16 dry skin 58 31 frequent (33%) Frequent (79-30%) HP:0000958
17 pruritus 58 31 frequent (33%) Frequent (79-30%) HP:0000989
18 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
19 papule 58 31 frequent (33%) Frequent (79-30%) HP:0200034
20 skin ulcer 58 31 frequent (33%) Frequent (79-30%) HP:0200042
21 chondrocalcinosis 58 31 frequent (33%) Frequent (79-30%) HP:0000934
22 pulmonary fibrosis 58 31 frequent (33%) Frequent (79-30%) HP:0002206
23 respiratory insufficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002093
24 abnormal hair quantity 58 31 frequent (33%) Frequent (79-30%) HP:0011362
25 interstitial pulmonary abnormality 58 31 frequent (33%) Frequent (79-30%) HP:0006530
26 diffuse reticular or finely nodular infiltrations 58 31 frequent (33%) Frequent (79-30%) HP:0002207
27 feeding difficulties in infancy 58 31 occasional (7.5%) Occasional (29-5%) HP:0008872
28 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
29 cutaneous photosensitivity 58 31 occasional (7.5%) Occasional (29-5%) HP:0000992
30 telangiectasia of the skin 58 31 occasional (7.5%) Occasional (29-5%) HP:0100585
31 myocardial infarction 58 31 occasional (7.5%) Occasional (29-5%) HP:0001658
32 pericarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001701
33 pulmonary arterial hypertension 58 31 occasional (7.5%) Occasional (29-5%) HP:0002092
34 gangrene 58 31 occasional (7.5%) Occasional (29-5%) HP:0100758
35 aplasia/hypoplasia of the skin 58 31 occasional (7.5%) Occasional (29-5%) HP:0008065
36 lymphoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0002665
37 cellulitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100658
38 dysphonia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001618
39 myocarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012819
40 vasculitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002633
41 breast carcinoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0003002
42 sinus tachycardia 58 31 occasional (7.5%) Occasional (29-5%) HP:0011703
43 lung adenocarcinoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0030078
44 gastrointestinal stroma tumor 58 31 occasional (7.5%) Occasional (29-5%) HP:0100723
45 abnormal eosinophil morphology 31 occasional (7.5%) HP:0001879
46 arrhythmia 58 Occasional (29-5%)
47 edema 58 Very frequent (99-80%)
48 neoplasm 58 Occasional (29-5%)
49 abnormality of the voice 58 Occasional (29-5%)
50 abnormality of the eyelid 58 Very frequent (99-80%)

UMLS symptoms related to Dermatomyositis:


pruritus, exanthema

Drugs & Therapeutics for Dermatomyositis

Drugs for Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Abatacept Approved Phase 4 332348-12-6 10237
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
5
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
6
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
7
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
8
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
9
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
10
Memantine Approved, Investigational Phase 4 19982-08-2 4054
11 Vaccines Phase 4
12 Melanocyte-Stimulating Hormones Phase 4
13 beta-Endorphin Phase 4
14 Antifungal Agents Phase 4
15 Protective Agents Phase 4
16 Neurotransmitter Agents Phase 4
17 Neuroprotective Agents Phase 4
18 Dopamine Agents Phase 4
19 Excitatory Amino Acid Antagonists Phase 4
20 Antiparkinson Agents Phase 4
21 Anticonvulsants Phase 4
22
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
23
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492 6473866
24
Alendronate Approved Phase 2, Phase 3 66376-36-1, 121268-17-5 2088
25
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
26
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
27
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
28 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
29
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
30
Infliximab Approved Phase 2, Phase 3 170277-31-3
31
Pirfenidone Approved, Investigational Phase 3 53179-13-8 40632
32
Ustekinumab Approved, Investigational Phase 3 815610-63-0
33
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
34
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
35
belimumab Approved Phase 2, Phase 3 356547-88-1 10451420 5957
36
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
37
Methotrexate Approved Phase 2, Phase 3 59-05-2, 1959-05-2 126941
38
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
39
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
40
Azathioprine Approved Phase 3 446-86-6 2265
41
Mycophenolic acid Approved Phase 3 24280-93-1 446541
42
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
43
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
44 Interleukin 1 Receptor Antagonist Protein Phase 2, Phase 3
45 Methylprednisolone Acetate Phase 2, Phase 3
46 Immunoglobulin G Phase 3
47 Antineoplastic Agents, Immunological Phase 2, Phase 3
48 Alkylating Agents Phase 2, Phase 3
49 Analgesics Phase 2, Phase 3
50 Analgesics, Non-Narcotic Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 121)
# Name Status NCT ID Phase Drugs
1 Randomized Controlled Trial of Pirfenidone in Patients With Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
2 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
3 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
4 Memantine for Corticosteroid-Induced Mood and Declarative Memory Changes: A Pilot Study Completed NCT00280774 Phase 4 Memantine
5 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
6 Abatacept for the Treatment of Refractory Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
7 Sirolimus in Patients With Connective Tissue Disease Related Thrombocytopenia (CTD-TP): a Single-arm, Open-label Clinical Trial in China Active, not recruiting NCT03688191 Phase 4 Sirolimus
8 Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes Terminated NCT00283309 Phase 4 Memantine;Riluzole
9 Five-year Single-blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine a Versus Prednisone Plus Methotrexate Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
10 Double Blind Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid-Associated Osteopenia and Osteoporosis Unknown status NCT00209469 Phase 2, Phase 3 alendronate sodium
11 Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis ("ProDERM Study") Completed NCT02728752 Phase 3 Octagam 10%
12 A Randomized, Double-blind, Controlled Clinical Study of GB-0998 for the Steroid-resistant Polymyositis and Dermatomyositis Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
13 Anakinra in Patients With Refractory Idiopathic Inflammatory Myopathies Completed NCT01165008 Phase 2, Phase 3 Anakinra
14 Double-Blinded Controlled Trial of Alendronate for the Treatment of Childhood and Adolescent Glucocorticoid- Associated Osteopenia and Osteoporosis Completed NCT00277251 Phase 2, Phase 3 Alendronate
15 An Open Trial With TNF Blockade With Infliximab (Remicade®), in Patients With Chronic Inflammatory Myopathies Completed NCT00443222 Phase 2, Phase 3 Infliximab
16 An Open-label Clinical Trial of the Combination Treatment of Tacrolimus and Corticosteroid in Polymyositis/Dermatomyositis Patients With Interstitial Pneumonitis, With Comparison Against Corticosteroid-treated Historical Controls Completed NCT00504348 Phase 2, Phase 3 Tacrolimus
17 A Prospective, Randomised, Assessor-blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With Polymyositis and Dermatomyositis. Completed NCT00651040 Phase 3 Prednisone;Methotrexate
18 A Phase III, Randomized, Double-blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Pirfenidone in Subjects With Dermatomyositis Interstitial Lung Disease (Dm-ILD) Recruiting NCT03857854 Phase 3 Pirfenidone;Placebos
19 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis Recruiting NCT03813160 Phase 3 Lenabasum 20 mg;Lenabasum 5 mg;Placebo
20 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments Recruiting NCT03981744 Phase 3 Ustekinumab 6 mg/kg;Ustekinumab 90 mg;Placebo IV;Placebo SC
21 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults With Dermatomyositis (DM) Active, not recruiting NCT04044690 Phase 3 human immunoglobulin G;Placebo
22 A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM) Active, not recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
23 A Randomized, Double Blind Controlled Trial Comparing Rituximab Against Intravenous Cyclophosphamide in Connective Tissue Disease Associated Interstitial Lung Disease Active, not recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
24 Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis Active, not recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
25 Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Subcutaneous Human Immunoglobulin (Octanorm) in Patients With Dermatomyositis (SCGAM-02) Terminated NCT03686969 Phase 3 Octanorm
26 Toward Improved Understanding of Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
27 Clinical Trial of Oral Medication for CTD-ILD Treatment Terminated NCT01424033 Phase 2, Phase 3 N-Acetylcysteine
28 A Randomized, Multicenter Study to Assess the Efficacy on Diseases Activity of Enteric-coated Mycophenolate Sodium Versus Continuation of Azathioprine in Patients With Systemic Lupus Erythematosus on Azathioprine Maintenance Therapy. Terminated NCT00504244 Phase 3 switch to Myfortic;continuation of azathioprine
29 Basiliximab as a Treatment of Interstitial Pneumonia in Clinical Amyopathic Dermatomyositis Patients Unknown status NCT03192657 Phase 2 Basiliximab;Calcineurin Inhibitors;Steroids
30 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2 Abatacept;Abatacept
31 Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis Completed NCT01572844 Phase 2 Sodium thiosulfate
32 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis Completed NCT02612857 Phase 2 IMO-8400 Dose Group 1;IMO-8400 Dose Group 2;Placebo
33 Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis Completed NCT01415219 Phase 2
34 Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
35 A Randomized, Third-Party-Blind, Placebo-Controlled Pilot Study of the Effect of h5G1.1-mAb on Dermatomyositis Patients Completed NCT00005571 Phase 2 h5G1.1-mAb
36 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Completed NCT02043548 Phase 2 tocilizumab;placebo
37 A Pilot Study of the Role of Methimazole in Patients With Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
38 The Efficacy of High-Dose Intravenous Immunoglobulin in Patients With Inflammatory Myopathies: A Three Month Randomized Trial With Option for Cross-Over Completed NCT00001261 Phase 2 Gamma Globulin
39 Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM) Completed NCT00106184 Phase 2 Rituximab;Placebo
40 Phase II Study of Prednisolone/Methylprednisolone Absorption in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
41 A Randomized, Double-Blind, Placebo-Controlled Trial of Infliximab in Patients With Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
42 A Phase 2 Open-label Study to Evaluate the Long-term Safety of Sifalimumab in Adult Subjects With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
43 Early Onset Immunotherapy by Intravenous Immunoglobulin in Well-characterized Onconeural-antibody-positive Paraneoplastic Neurological Syndromes Completed NCT02343211 Phase 2 Immunoglobulin
44 A Randomized Double Blind Placebo Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin (IVIG) in Children With Japanese Encephalitis in Nepal Completed NCT01856205 Phase 2 Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]
45 An Open-label Study of Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
46 A Phase 2, Open Label Single Arm Study for Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis Recruiting NCT03529955 Phase 2 Apremilast 30mg
47 A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis Recruiting NCT04033926 Phase 2 KZR-616;Placebo
48 An Open Label, Multi-centered, Randomized Phase 2 Study to Evaluate the Safety, Tolerability and Bioactivity of Subcutaneous ACTH GeL in PAtients With Scleritis: The ATLAS Study Recruiting NCT03465111 Phase 2 ACTH (adrenocorticotropic hormone) gel
49 A PHASE 2A, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS Active, not recruiting NCT03181893 Phase 2 PF-06823859;Placebo Arm
50 A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis Active, not recruiting NCT02466243 Phase 2 JBT-101;Placebo

Search NIH Clinical Center for Dermatomyositis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Immunoglobulins, Intravenous
Potassium aminobenzoate

Cochrane evidence based reviews: dermatomyositis

Genetic Tests for Dermatomyositis

Anatomical Context for Dermatomyositis

The Foundational Model of Anatomy Ontology organs/tissues related to Dermatomyositis:

19
Muscle, Skin Where A Skin Rash Is Often Seen Prior To The Onset Of Muscle Weakness

MalaCards organs/tissues related to Dermatomyositis:

40
Lung, Skin, T Cells, Breast, Skeletal Muscle, Heart, Bone

Publications for Dermatomyositis

Articles related to Dermatomyositis:

(show top 50) (show all 8687)
# Title Authors PMID Year
1
Distinctive patterns of microRNA expression in primary muscular disorders. 46 61
17942673 2007
2
Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis. 54 61
19953283 2010
3
A dual role for HSP90 and HSP70 in the inflammatory myopathies: from muscle fiber protection to active invasion by macrophages. 54 61
19758187 2009
4
Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins. 54 61
19303320 2009
5
An evaluation of the efficacy of the toe brachial index measuring vascular involvement in systemic sclerosis and other connective tissue diseases. 54 61
19796558 2009
6
Nonspecific interstitial pneumonia associated with collagen vascular disease: analysis of CT features to distinguish the various types. 54 61
19443969 2009
7
Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis. 54 61
18578962 2008
8
Inducible overexpression of wild-type prion protein in the muscles leads to a primary myopathy in transgenic mice. 61 54
17420473 2007
9
Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. 61 54
17265504 2007
10
Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review. 54 61
17207162 2007
11
Signs of inflammation in both symptomatic and asymptomatic muscles from patients with polymyositis and dermatomyositis. 61 54
16831829 2006
12
MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement. 61 54
16859997 2006
13
Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. 61 54
16431335 2006
14
Autoantibodies against the replication protein A complex in systemic lupus erythematosus and other autoimmune diseases. 54 61
16846524 2006
15
[Pravastatin-induced dermatomyositis]. 54 61
16154665 2005
16
Diagnostic significance of membrane attack complex and vitronectin in childhood dermatomyositis. 54 61
16159528 2005
17
Chemokine receptor CCR7 is expressed in muscle fibers in juvenile dermatomyositis. 61 54
15950936 2005
18
Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. 61 54
15894686 2005
19
Changes of single fiber electromyography in patients with inflammatory myopathies. 61 54
15844301 2005
20
[A case of dermatomyositis associated with different types of cancers at intervals of six years]. 54 61
15678898 2004
21
Mitochondrial abnormalities in dermatomyositis: characteristic pattern of neuropathology. 61 54
15614615 2004
22
Dermatomyositis associated with Sjögren's syndrome: VEGF involvement in vasculitis. 61 54
15328883 2004
23
Immunohistochemical analysis of adhesion molecule expression on muscle biopsy specimens from patients with juvenile dermatomyositis. 61 54
15088312 2004
24
Immunolocalization of protectin (CD59) and macrophages in polymyositis and dermatomyositis. 61 54
15020079 2004
25
Anticyclic citrullinated peptide antibodies in patients with mixed connective tissue disease. 61 54
17143695 2004
26
Cytokines in juvenile dermatomyositis pathophysiology: potential and challenge. 61 54
14569197 2003
27
Update on juvenile dermatomyositis: new advances in understanding its etiopathogenesis. 54 61
12960487 2003
28
Expression of calcium-binding proteins MRP8 and MRP14 in inflammatory muscle diseases. 54 61
12937135 2003
29
Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. 54 61
12667656 2003
30
Relationship between utrophin and regenerating muscle fibers in duchenne muscular dystrophy. 54 61
12619170 2003
31
Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease. 54 61
12421999 2002
32
Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. 54 61
12235211 2002
33
[A case of amyopathic dermatomyositis with systemic sclerosis sine scleroderma presenting abnormal vermiculation]. 54 61
12355862 2002
34
Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis. 54 61
12173300 2002
35
Overview of neuromuscular disorders affecting respiratory function. 61 54
16088611 2002
36
Interleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. 54 61
11953983 2002
37
Cardiac troponin and beta-type myosin heavy chain concentrations in patients with polymyositis or dermatomyositis. 54 61
11282091 2001
38
Increased expression of the normal cellular isoform of prion protein in inclusion-body myositis, inflammatory myopathies and denervation atrophy. 54 61
11303793 2001
39
Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. 54 61
11083269 2000
40
Increased interleukin-17 production in patients with systemic sclerosis. 61 54
11083268 2000
41
Increased CD40 expression on muscle cells of polymyositis and dermatomyositis: role of CD40-CD40 ligand interaction in IL-6, IL-8, IL-15, and monocyte chemoattractant protein-1 production. 61 54
10843719 2000
42
Kinetics of anti-fibrillin-1 autoantibodies in MCTD and CREST syndrome. 54 61
10756089 2000
43
Abnormal IL-1 receptor antagonist production in patients with polymyositis and dermatomyositis. 61 54
10732829 2000
44
Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies. 61 54
10749105 2000
45
Dermatomyositis with erosive arthropathy: association with the anti-PL-7 antibody. 61 54
10606385 1999
46
[Cytomegalovirus infection associated with immunosuppressive therapy in collagen vascular diseases]. 61 54
10614168 1999
47
[Amyopathic dermatomyositis with interstitial pneumonia: effective treatment with cyclophosphamide pulse therapy]. 54 61
10496106 1999
48
Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. 61 54
10444360 1999
49
[Expression of adhesion molecules in idiopathic inflammatory myopathies. Immunohistochemical study of 17 cases]. 61 54
10320905 1999
50
Dermatomyositis and drugs. 61 54
10599342 1999

Variations for Dermatomyositis

Expression for Dermatomyositis

Search GEO for disease gene expression data for Dermatomyositis.

Pathways for Dermatomyositis

Pathways related to Dermatomyositis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.85 MIR34A MIR335 MIR30A MIR223 MIR222 MIR221
2 11.03 MIR222 MIR221 MIR210
3 10.71 MIR222 MIR221 MIR146B

GO Terms for Dermatomyositis

Cellular components related to Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 MIR335 MIR30A MIR223 MIR222 MIR221 MIR210
2 extracellular vesicle GO:1903561 9.23 MIR34A MIR30A MIR222 MIR221 MIR214 MIR21

Biological processes related to Dermatomyositis according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.05 MIR34A MIR30A MIR223 MIR21 MIR155 MIR154
2 negative regulation of gene expression GO:0010629 10.04 MIR214 MIR21 MIR155 MIR154 MIR132
3 positive regulation of protein kinase B signaling GO:0051897 9.96 MIR222 MIR221 MIR21 MIR199B MIR132
4 negative regulation of inflammatory response GO:0050728 9.94 MIR223 MIR222 MIR221 MIR155
5 negative regulation of angiogenesis GO:0016525 9.92 MIR34A MIR222 MIR214 MIR21
6 cholesterol homeostasis GO:0042632 9.88 MIR34A MIR155 MIR148A MIR132
7 cellular response to hypoxia GO:0071456 9.86 MIR34A MIR214 MIR155
8 positive regulation of blood vessel endothelial cell migration GO:0043536 9.83 MIR30A MIR221 MIR210
9 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.83 MIR221 MIR199B MIR155 MIR146B
10 positive regulation of epithelial to mesenchymal transition GO:0010718 9.82 MIR222 MIR221 MIR21
11 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.81 MIR223 MIR21 MIR132
12 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.8 MIR222 MIR221 MIR155
13 positive regulation of angiogenesis GO:0045766 9.8 MIR30A MIR210 MIR21 MIR199B MIR132 MIR130A
14 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.76 MIR30A MIR222 MIR221 MIR214
15 positive regulation of vascular endothelial cell proliferation GO:1905564 9.75 MIR21 MIR132 MIR130A
16 negative regulation of necroptotic process GO:0060546 9.74 MIR221 MIR214 MIR155
17 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.73 MIR362 MIR34A MIR223 MIR214
18 positive regulation of connective tissue replacement GO:1905205 9.72 MIR34A MIR214 MIR155
19 negative regulation of cell adhesion molecule production GO:0060354 9.71 MIR222 MIR221 MIR155
20 positive regulation of cardiac muscle hypertrophy GO:0010613 9.69 MIR21 MIR155
21 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.69 MIR21 MIR132
22 negative regulation of innate immune response GO:0045824 9.68 MIR21 MIR155
23 positive regulation of endothelial cell differentiation GO:0045603 9.68 MIR21 MIR199B
24 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.68 MIR155 MIR148A
25 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.68 MIR214 MIR155
26 positive regulation of axon regeneration GO:0048680 9.67 MIR222 MIR221
27 negative regulation of interleukin-8 production GO:0032717 9.67 MIR155 MIR132
28 negative regulation of vascular wound healing GO:0061044 9.67 MIR34A MIR155
29 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.67 MIR222 MIR221 MIR155
30 negative regulation of regulatory T cell differentiation GO:0045590 9.66 MIR21 MIR155
31 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.66 MIR210 MIR21
32 negative regulation of necrotic cell death GO:0060547 9.65 MIR223 MIR155
33 negative regulation by host of viral genome replication GO:0044828 9.65 MIR222 MIR221 MIR155
34 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.65 MIR222 MIR221 MIR214 MIR21 MIR130A
35 positive regulation of vascular smooth muscle cell dedifferentiation GO:1905176 9.62 MIR221 MIR214
36 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.61 MIR222 MIR221
37 positive regulation of Schwann cell migration GO:1900149 9.61 MIR222 MIR221
38 miRNA mediated inhibition of translation GO:0035278 9.61 MIR30A MIR299 MIR222 MIR221 MIR210 MIR21
39 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.6 MIR222 MIR221
40 gene silencing by miRNA GO:0035195 9.6 MIR362 MIR34A MIR335 MIR30A MIR299 MIR223
41 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.59 MIR222 MIR221
42 negative regulation of interleukin-21 biosynthetic process GO:0045391 9.58 MIR222 MIR221 MIR21
43 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.55 MIR362 MIR34A MIR223 MIR214 MIR21
44 negative regulation of interleukin-21 production GO:0032705 9.54 MIR222 MIR221 MIR21

Molecular functions related to Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.58 MIR362 MIR34A MIR30A MIR299 MIR223 MIR222

Sources for Dermatomyositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....